This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
391
Relative change from baseline in body weight percentage
Time frame: Baseline to Week 48
Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%
Time frame: Baseline to Week 48
Change from baseline in lipids
Time frame: Baseline to Week 48
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time frame: Baseline to Week 48
Changes from baseline in Fasting Glucose
Time frame: Baseline to Week 48
Changes from baseline in Hemoglobin A1c
Time frame: Baseline to Week 48
Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)
Time frame: Baseline to Week 48
Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure
Time frame: Baseline to Week 48
Change from baseline in proportion of patients using antihypertensive medications
Time frame: Baseline to Week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Altimmune CTM
Birmingham, Alabama, United States
Altimmune CTM
Mesa, Arizona, United States
Altimmune CTM
Los Angeles, California, United States
National Research Institute
Los Angeles, California, United States
Altimmune CTM
Montclair, California, United States
Altimmune CTM
Santa Barbara, California, United States
Altimmune CTM
Boca Raton, Florida, United States
Altimmune CTM
Clearwater, Florida, United States
Altimmune CTM
Fort Myers, Florida, United States
Altimmune CTM
Jacksonville, Florida, United States
...and 21 more locations